Becotatug Vedotin: First Approval.

Becotatug vedotin (MEIYOUHENG®), an antibody drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR), is being developed by Lepu Biopharma for the treatment of various cancers. In October 2025, becotatug vedotin received its first approval in China for the treatment of adult patients with recurrent/metastatic nasopharyngeal carcinoma who have failed at least two lines of systemic chemotherapy and programmed death-1 (PD-1)/programmed death-1 ligand (PD-L1) inhibitor therapy. This article summarizes the milestones in the development of becotatug vedotin leading to this first approval for nasopharyngeal cancer.